| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 05/02/2002 | WO2001055210A3 Human cyr61 |
| 05/02/2002 | WO2001054686A3 L-arginine in combination with other compounds for treating cardiovascular diseases |
| 05/02/2002 | WO2001052829A3 Statin-type bone growth stimulators |
| 05/02/2002 | WO2001051635A3 Novel stra6 polypeptides |
| 05/02/2002 | WO2001048209A3 Genes identified as required for proliferation of e. coli |
| 05/02/2002 | WO2001046394A3 Mammalian protein phosphatases |
| 05/02/2002 | WO2001045667A3 Water-soluble powders for oral solution and use thereof |
| 05/02/2002 | WO2001042207A3 Novel methods for the treatment and prevention of ileus |
| 05/02/2002 | WO2001039762A3 Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system |
| 05/02/2002 | WO2001036979A3 Placental human neurokinin b precursor |
| 05/02/2002 | WO2001035949A3 Treatment or systemic lupus erythematosus (sle) with dehydroepiandrosterone |
| 05/02/2002 | WO2001029071A3 Genes associated with obesity and methods for using the same |
| 05/02/2002 | WO2001024828A3 MODULATORS OF CYTOKINE MEDIATED SIGNALLING PATHWAYS AND INTEGRIN αVβ3 RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY |
| 05/02/2002 | WO2001018172A3 Fibroblast growth factor-like polypeptides |
| 05/02/2002 | WO2001008671A3 Method and composition for prophylaxis and treatment of symptoms associated with cold and influenza-like illnesses |
| 05/02/2002 | WO2001007651A3 Transposon mediated differential hybridisation |
| 05/02/2002 | WO2001000874A3 Cancer associated antigens and uses therefor |
| 05/02/2002 | WO2000078972A3 Regulation with binding cassette transporter protein abc1 |
| 05/02/2002 | WO2000075365A9 COMPOUNDS AND METHODS TO ENHANCE rAAV TRANSDUCTION |
| 05/02/2002 | WO2000059491A3 Methods for modulating the human sexual response |
| 05/02/2002 | US20020053093 By use of biological agents which either recognize an extracellular domain of prostate specific membrane antigen or bind to and are internalized with prostate specific membrane antigen |
| 05/02/2002 | US20020053091 Isolated human G-protein coupled receptors, nucleic acid molecules encoding human GPCR proteins, and uses thereof |
| 05/02/2002 | US20020052693 Pharmacophore models for, methods of screening for, and identification of the cytochrome P-450 inhibitory potency of neurokinin-1 receptor antagonists |
| 05/02/2002 | US20020052594 Method and kit for imaging and treating organs and tissues |
| 05/02/2002 | US20020052513 Oxamide IMPDH inhibitors |
| 05/02/2002 | US20020052477 Fibroblast growth factor homologous factor-1 (fhf-1) and methods of use |
| 05/02/2002 | US20020052443 Non-antigenic branched polymer conjugates |
| 05/02/2002 | US20020052420 Inhibiting or preventing a condition associated with undesired secretion of a macrophage inflammatory protein using inhibitors of inosine or inosine derivatives useful for treating inflammatory bowel disease |
| 05/02/2002 | US20020052416 Use of prostaglandin EP-3 receptor antagonists as cosmetic agents for attenuating, reducing or stopping the loss of head hair and other hairs |
| 05/02/2002 | US20020052407 Modulating expression, production, or formation of amyloid precursor protein by administering a nonsteroidal antiinflammatory agent that is a cyclooxygenase inhibitor |
| 05/02/2002 | US20020052404 Compositions and methods for treating or preventing diseases of body passageways |
| 05/02/2002 | US20020052392 Have utility as, inter alia, hypoglycemic, and anti-obesity agents. |
| 05/02/2002 | US20020052390 Treating non-invasive fungus-induced otitis media by mucoadministering an antifungal agent. |
| 05/02/2002 | US20020052373 D4 dopamine receptor in combination with an acetylcholine esterase inhibitor. |
| 05/02/2002 | US20020052372 Using neurotrophic pipecolic acid derivative compounds having an affinity for FKBP-type immunophilins as inhibitors of the enzyme activity associated with immunophilin proteins |
| 05/02/2002 | US20020052370 Including the treatment of female sexual dysfunction especially female sexual arousal disorder |
| 05/02/2002 | US20020052366 Administering taurolidine, taurultam, or a biologically active derivative; induces tumor cell death by apoptosis. |
| 05/02/2002 | US20020052365 Selective anxiolytic therapeutic agents |
| 05/02/2002 | US20020052363 Piperazine- or diazepine-containing compounds; useful in the treatment of cancer. |
| 05/02/2002 | US20020052358 Methods and compositions related to modulators of annexin and cartilage homeostasis |
| 05/02/2002 | US20020052356 Quinoline and quinazoline derivatives; prophylaxis or treatment of arthritis, cardiovascular diseases, diabetes, renal failure and particularly eating disorders and obesity. |
| 05/02/2002 | US20020052351 Novel medical use for tachykinin antagonists |
| 05/02/2002 | US20020052347 Protein tyrosine phosphatase 1B (PTP-1B) inhibitors containing two ortho-substituted aromatic phosphonates |
| 05/02/2002 | US20020052346 Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B) |
| 05/02/2002 | US20020052344 Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase IB (PTP-IB) |
| 05/02/2002 | US20020052341 Bupropion metabolites and methods of their synthesis and use |
| 05/02/2002 | US20020052340 Treating disorders ameliorated by inhibition of neuronal monoamine reuptake, such as erectile dysfunction, affective disorders, cerebral function disorders, cigarette smoking, and incontinence. |
| 05/02/2002 | US20020052337 Composition and method for inhibiting platelet aggregation |
| 05/02/2002 | US20020052326 Treating diabetes and related diseases in combination with one, two or more other antidiabetic agents and/or one, two or more hypolipidemic agents. |
| 05/02/2002 | US20020052324 Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor |
| 05/02/2002 | US20020052319 Topical anesthetic/opioid formulations and uses thereof |
| 05/02/2002 | US20020052317 Anti-viral and anti-tumor chemotherapy by administration of erythropoeitin |
| 05/02/2002 | US20020052316 Bax-mediated apoptosis modulating reagents and methods |
| 05/02/2002 | US20020052309 Use of human erythropoietin (EPO) to prevent or treat endothelial injury due to chemotherapy, radiation therapy, mechanical trauma, or to a disease state which damages the endothelium |
| 05/02/2002 | US20020052038 Polypeptide for use in the treatment of viral diseases and cancer |
| 05/02/2002 | US20020052033 Novel low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis |
| 05/02/2002 | US20020052027 IL-17 homologous polypeptides and therapeutic uses thereof |
| 05/02/2002 | US20020052013 Tumour-specific P450 protein |
| 05/02/2002 | US20020051814 Composition for the treatment and prevention of ischemic events |
| 05/02/2002 | US20020051811 Method and composition for masking mineral taste |
| 05/02/2002 | US20020051807 Controlled release alprazolam in the core optionally in combination with an anti-psychotic agent, in a rapid release external coat; smaller, easier to swallow |
| 05/02/2002 | US20020051799 Glucosylated hydroxystilbene compounds for treating skin conditions |
| 05/02/2002 | US20020051766 Treating an aliquot of patient's blood ex vivo with a stressor selected from temperature above or below body temperature, an electromagnetic emission and an oxidative environment, followed by administering back into patient |
| 05/02/2002 | US20020051760 Method for screening a substance having promoting activity on hair growth |
| 05/02/2002 | US20020051753 Comprising a pressure-sensitive adhesive layer containing a drug on a cloth which prevents the dilution of drug by saliva |
| 05/02/2002 | US20020051749 Use of biodegradable microspheres that release an anticancer agent for treating gliobastoma |
| 05/02/2002 | EP1202065A1 Net, a transcription factor of the TCF family, as regulator of angiogenic expression. |
| 05/02/2002 | EP1201764A2 Assays for identifying phosphatase inhibitors |
| 05/02/2002 | EP1201660A1 Glucocorticoid receptor modulators |
| 05/02/2002 | EP1201649A1 Glucocorticoid receptor modulators |
| 05/02/2002 | EP1201268A2 Combinations of D4 dopamine receptor antagonists with acetylcholine esterase inhibitors |
| 05/02/2002 | EP1201248A2 Combination therapy of angiotensin converting enzyme inhibitor, side-effect reduced amount of aldosterone antagonist and diuretic for treatment of cardiovascular disease |
| 05/02/2002 | EP1201247A2 Treatment of tumor metastases and cancer |
| 05/02/2002 | EP1201241A2 Compositions containing capsaicin or capsaicin analogues and a local anesthetic |
| 05/02/2002 | EP1201240A2 Heterocyclic derivatives useful as pharmaceutical agents |
| 05/02/2002 | EP1201233A1 Transdermal dosage form |
| 05/02/2002 | EP1201227A2 Use of flavonoids as immunomodulating or immunoprotecting agents in cosmetic and dermatological compositions |
| 05/02/2002 | EP1200835A1 Methods for identification of compounds stimulating insulin secretion |
| 05/02/2002 | EP1200831A1 Modulating binding site on potassium channels used for screening |
| 05/02/2002 | EP1200623A2 Diagnostic method comprising wt1 sequences |
| 05/02/2002 | EP1200616A2 Enhanced delivery via serpin enzyme complex receptor ligands |
| 05/02/2002 | EP1200602A1 Dsp-11 dual-specificity map kinase phophatase |
| 05/02/2002 | EP1200599A1 CRYSTALLIZATION AND STRUCTURE DETERMINATION OF STPHYLOCOCCUS AUREUS UDP-N-ACETYLENOLPYRUVYLGLUCOSAMINE REDUCTASE (S. AUREUS MurB) |
| 05/02/2002 | EP1200596A2 Human synthetases |
| 05/02/2002 | EP1200595A2 Myxoma virus genes for immune modulation |
| 05/02/2002 | EP1200591A1 Human homologue of bovine neuroendocrine secretory protein, nesp55, polynucleotides and uses thereof linked with obesity |
| 05/02/2002 | EP1200587A2 Receptors and associated proteins |
| 05/02/2002 | EP1200586A2 Human nervous system-associated proteins |
| 05/02/2002 | EP1200572A1 Antisense modulation of liver glycogen phosphorylase expression |
| 05/02/2002 | EP1200519A1 Pre-formed, self-adhesive sheet devices suitable for topical application |
| 05/02/2002 | EP1200472A1 Odorant receptors |
| 05/02/2002 | EP1200470A2 Globular assembly of amyloid beta protein and uses thereof |
| 05/02/2002 | EP1200468A1 CRYSTALLIZATION AND STRUCTURE DETERMINATION OF i STAPHYLOCOCCUS AUREUS /i ELONGATION FACTOR P |
| 05/02/2002 | EP1200461A2 Polypeptide dendrimers as unimolecular carriers of diagnostic imaging contrast agents, bioactive substances and drugs |
| 05/02/2002 | EP1200458A1 Uses of peptides derived from the cytoplasmic domain of the amyloid protein precursor (app) |
| 05/02/2002 | EP1200445A1 Thienopyranecarboxamide derivatives |
| 05/02/2002 | EP1200432A1 Amido spiropiperidines promote the release of growth hormone |
| 05/02/2002 | EP1200422A2 Pyrazole compositions useful as inhibitors of erk |
| 05/02/2002 | EP1200140A1 Controlled release implantable devices |
| 05/02/2002 | EP1200137A1 Agent for occluding blood vessels |